改良INP方案对肺腺癌脑转移患者的疗效分析

doi:10.3969/j.issn.1000-8535.2015.04.004

广州医药 ›› 2015, Vol. 46 ›› Issue (4): 13-16.DOI: 10.3969/j.issn.1000-8535.2015.04.004

改良INP方案对肺腺癌脑转移患者的疗效分析

张亚雷¹, 杨海虹¹, 邓秋华¹, 何绮华¹, 徐光川², 何建行¹

1 广州医科大学附属第一医院胸外科广州呼吸疾病研究所(广州 510120)
2 中山大学肿瘤医院(广州 510060)

收稿日期:2015-02-27 发布日期:2021-11-30
通讯作者: 何建行,E-mail:hjx@vip.163.com
基金资助:
广州市医药卫生科技项目(20131A011135)

Efficacy of chemotherapy of modified INP regimen for adenocarcinoma with brain metastases

Zhang Yalei, Yang Haihong, Deng Qiuhua, Xu Guangchun, et al

The First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;
Sun-Yat-Sen University Cancer Center, Guangzhou 510060,China

Received:2015-02-27 Published:2021-11-30

摘要/Abstract

摘要： 目的观察改良INP方案对肺腺癌伴有脑转移患者的临床疗效及毒副作用,并探讨该方案疗效与Ⅲ型β微管蛋白(β-tubulin-Ⅲ)在肺癌组织中表达水平的关系。方法收集2010年4月—2013年1月广州医科大学附属第一医院胸外科收治的15例肺腺癌伴有脑转移患者的临床资料。所有患者均采用改良INP方案治疗,使用RECIST 1.0标准进行判定。结果脑转移瘤取得CR 1例(1/15),PR 5例(5/15),SD 4例(4/15),PD 5例 (5/10),该方案对脑转移瘤的总缓解率(overall response rate,ORR)为40%,疾病控制率(disease control rate,DCR)达66.7%,毒副作用轻度可控;Ⅲ型β微管蛋白低表达对该方案的疗效有优于高表达的趋势。结论肺腺癌伴有脑转移患者采用改良INP方案进行化疗,脑转移瘤临床疾病控制率较高,耐受性良好;肿瘤组织β-tubulin-Ⅲ表达水平可能与该方案的疗效相关。

关键词: 肺腺癌, 异环磷酰胺, 长春瑞滨, β微管蛋白Ⅲ型, 脑转移癌

Abstract: Objective To investigate the efficacy and toxicity of chemotherapy of modified INP regimen in the treatment of adenocarcinoma with brain metastases. At the same time,to explore the relationship between expression of β-tubulin-Ⅲ in NSCLC biopsies and sensitivity to this modified INP regimen. Methods The clinical data of 15 adenocarcinoma with brain metastases patients who had been admitted to the first affiliated hospital of Guangzhou medical university from April 2010 to January 2013 were retrospectively analyzed. All patients received modified INP regimen.RECIST 1.0 was taken to know the result. Results For brain metastasis of the 15 patients, complete response (CR) and partial response(PR) were 1 and 5 patients, respectively. 4 patients were stable disease (SD) and progression disease(PD) in 5 patients. The overall response rate(ORR) was 40% and the disease control rate(DCR) was 66.7%. The toxicity was mild. Furthermore, we found NSCLC patients with low β-tubulin-Ⅲexpression had better ORR than those with high expression. Conclusion The modified INP regimen is effective and well-tolerable for brain metastases of adenocarcinoma. The β-tubulin-Ⅲ expression may be associated with the efficacy of this regimen.

Key words: Adenocarcinoma, Ifosfamide, Vinorelbine, β-tubulin-Ⅲ, Brain metastases

张亚雷, 杨海虹, 邓秋华, 何绮华, 徐光川, 何建行. 改良INP方案对肺腺癌脑转移患者的疗效分析[J]. 广州医药, 2015, 46(4): 13-16.

Zhang Yalei, Yang Haihong, Deng Qiuhua, Xu Guangchun, et al. Efficacy of chemotherapy of modified INP regimen for adenocarcinoma with brain metastases[J]. Guangzhou Medical Journal, 2015, 46(4): 13-16.

参考文献

[1] Pirker R. Two-versus three-drug combinations in the chemotherapy of advanced non-small cell lung cancer[J]. Lung Cancer, 2002,38 (Suppl 3):S53-S55.
[2] Baykara M, Kurt G, Buyukberber S, et al. Management of brain metastases from non-small cell lung cancer[J]. J Cancer Res Ther,2014,10(4):915-21.
[3] 吴煌坚,蔡悦成,李曙平,等.23例脑转移的放射治疗[J]. 广州医药,2002,33(6):11-12
[4] Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain?[J]. Cancer Chemother Pharmacol, 1992,30(4):251-260
[5] Furuse K,Kamimori T,Kawahara M. A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin,vindesine and mitomycin in non-small cell lung cancer with brain metastasis[J]. Br J Cancer, 1997,75(4):614-618.
[6] Quantin X, Khial F, Reme Saumon M. Concomitant brain radiotherapy and vinorelbine-ifosfamind-cisplatin chemotherapy in brain metastases of non-small cell lung cancer[J]. Lung cancer,1999,26(1):35-39
[7] 宋俊彪,路萍.国产长春.瑞滨联合顺铂治疗晚期非小细胞肺癌的临床观察[J]. 哈尔滨医药,2006,26(6):2-4.
[8] Lucie L,Donald JM,Willian H,et al. Use of ifosfamide,carboplatin,and etoposide chemotherapy in choroids plexus carcinoma[J]. Journal of Neurosurgery:Pediatrics,2010,5(6):615-621
[9] Snson M,Ameri A,Monjour A,et al. Treatment of recurrent malignant supratentorial gliomas with ifosfamide,carboplatin and etoposide:a phase Ⅱ study[J]. Eur J Cancer,1996,(32A):2229-2235.
[10] Yang YL, Luo XP, Xian L.The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis[J]. PLoS One, 2014,9(4):e93997.
[11] Rosell R,Scagliotti G,Danenberg KD,et al. Transcfipts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small cell lung cancer[J]. Onengene,2003,22(23):3548-3553.
[12] 梁颖,徐光川,陈丽昆,等.INP和NP方案治疗晚期非小细胞肺癌的随机研究[J]. 中山大学学报(医学科学版), 2004,25(3S):225-228.
[13] 张亚雷,杨海虹,邓秋华,等.改良INP方案对晚期非小细胞肺癌患者疗效分析[J]. 实用肿瘤杂志,2013,3(28):312-315.

改良INP方案对肺腺癌脑转移患者的疗效分析

Efficacy of chemotherapy of modified INP regimen for adenocarcinoma with brain metastases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价